Replies to post #212362 on Biotech Values

[biomaven0]

>>"Ronin"), collectively the second largest stockholder of Peregrine Pharmaceuticals

That statement right there undermines any credibility they might have. :)

[jq1234]

>> (PPHM Bavituximab) Suspend All Clinical Development Activities

All clinical development activities should be immediately halted and the Company's cost structure must be adjusted accordingly. In the last decade, we estimate that Peregrine has spent over $300 million cumulatively in research and development on clinical development activities, which are almost entirely related to bavituximab, a drug which has been unsuccessful in numerous clinical studies, most recently failing a Phase III SUNRISE trial in February 2016 for small cell lung cancer. It has shown similarly disappointing results for breast cancer, hepatitis C, and pancreatic cancer. Given bavituximab's poor performance in clinical trials, it is questionable whether any further spending on its development is warranted at all;



Isn't this obvious to most for how many years? I guess it takes activist investors to tell the diehards.

[DewDiligence]

PPHM responds to activist’s letter:

https://finance.yahoo.com/news/peregrine-pharmaceuticals-issues-statement-regarding-220859104.html

“Peregrine welcomes the input of our stockholders and is committed to maintaining a highly qualified Board to lead the company forward.

...Our Nominating Committee will carefully evaluate Ronin/SWIM’s nominees consistent with that process. Following the Committee’s review, it will make a recommendation to the Board that is in the best interests of Peregrine and all of our stockholders. Stockholders need take no action at this time.”

LOL

[biopharm]

I wouldn't fall for Ronin without more info...they may have conflicts of interest to active pharmaceutical ingredient supplier ties to Big Pharma and APIs ready to rise

In another embodiment, the active pharmaceutical ingredient is an antineoplastic, for example an antineoplastic MAb. Exemplary antineoplastics include Bavituximab, Onartuzumab, yttrium Y-90 clivatuzumab tetraxetan, obinutuzumab, cixutumumab, necitumumab, pertuzumab, brentuximab vedotin, nivolumab, trastuzumab emtansine, siltuximab, elotuzumab, ramucirumab, trastuzumab emtansin, Ipilimumab, Rituximab, Trastuzumab, Pertuzumab, and bevacizumab.
http://www.google.com.pg/patents/US9474688

Lots of uses for Bavituximab....
Titanium and its alloys are widely employed materials for implants in orthopedic or dental surgery due to their mechanical properties, resistance to corrosion and osseointegration capability. However adverse reactions at the tissue/implant interface may occur, which limit the success of the osseointegration process. Therefore, different strategies have to be used to overcome these drawbacks. In this work, we developed two different liposome-based coatings on titanium surfaces as drug or bioactive molecule deposits for dental/orthopedic implant applications.